Omeros Corporation Market Cap ($1.32 Billion)
Market Cap & Net Worth: Omeros Corporation (OMER)
Omeros Corporation market cap. Omeros Corporation (NASDAQ:OMER) has a market capitalization of $1.32 Billion ($1.32 Billion) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7460 globally and #2284 in its home market, demonstrating a 12.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Omeros Corporation's stock price $18.27 by its total outstanding shares 72388316 (72.39 Million). Also see OMER cash flow conversion for how efficiently the company converts equity into cash flow.
Omeros Corporation Market Cap History (2015–2026)
Omeros Corporation market cap history from 2015 to 2026. Data shows growth from $1.14 Billion to $1.32 Billion (3.30% CAGR). Check current stock price of Omeros Corporation for real-time trading data and today's change.
Index Memberships
Omeros Corporation is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.05% | #217 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #838 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.07% | #128 of 263 |
Weight: Omeros Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Omeros Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Omeros Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Omeros Corporation equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.14x
Omeros Corporation's market cap is 5.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $718.09 Million | $41.62 Million | -$66.75 Million | 17.25x | N/A |
| 2017 | $1.41 Billion | $64.83 Million | -$53.48 Million | 21.70x | N/A |
| 2018 | $806.41 Million | $29.87 Million | -$126.76 Million | 27.00x | N/A |
| 2019 | $1.02 Billion | $111.81 Million | -$84.49 Million | 9.12x | N/A |
| 2020 | $1.03 Billion | $73.81 Million | -$138.06 Million | 14.01x | N/A |
| 2021 | $465.46 Million | $90.52 Million | -$111.41 Million | 5.14x | N/A |
Competitor Companies of OMER by Market Capitalization
Companies near Omeros Corporation in the global market cap rankings as of November 4, 2026. Also see Omeros Corporation total assets for a full breakdown of the balance sheet.
Key companies related to Omeros Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Omeros Corporation (2015–2026)
Market capitalization of Omeros Corporation from 2015 to today. Between 2015 and today, Omeros Corporation's market cap moved from $1.14 Billion to $ 1.32 Billion, with a yearly change of 3.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.32 Billion | +6.38% |
| 2025 | $1.24 Billion | +73.84% |
| 2024 | $715.20 Million | +202.14% |
| 2023 | $236.71 Million | +44.69% |
| 2022 | $163.60 Million | -64.85% |
| 2021 | $465.46 Million | -54.99% |
| 2020 | $1.03 Billion | +1.38% |
| 2019 | $1.02 Billion | +26.48% |
| 2018 | $806.41 Million | -42.67% |
| 2017 | $1.41 Billion | +95.87% |
| 2016 | $718.09 Million | -36.94% |
| 2015 | $1.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Omeros Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.32 Billion USD |
| MoneyControl | $1.32 Billion USD |
| MarketWatch | $1.32 Billion USD |
| marketcap.company | $1.32 Billion USD |
| Reuters | $1.32 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more